Background Inflammatory bowel diseases [IBD]―ulcerative colitis and Crohn's disease―are
commonly treated with biologic drugs. However, only approximately two-thirds of patients …

Inflammatory bowel disease (IBD) is a chronic immune-mediated inflammation of the
gastrointestinal tract with a highly heterogeneous presentation. It has a relapsing and …

Objective We aimed to provide an evidence-supported update of the ECCO-ESPGHAN
guideline on the medical management of paediatric Crohn's disease [CD]. Methods We …

Background: The contemporary management of ambulatory ulcerative colitis (UC) continues
to be challenging with∼ 20% of children needing a colectomy within childhood years. We …

Very early onset inflammatory bowel disease (VEO-IBD) is defined as IBD presenting before
6 years of age. When compared with IBD diagnosed in older children, VEO-IBD has some …

Inflammatory bowel diseases (IBD), including Crohn's disease and ulcerative colitis, are
lifelong conditions that often begin in childhood. The implications of IBD are of particular …

Cytokines play an important role in the immunopathogenesis of inflammatory bowel disease
(IBD), including Crohn's disease and ulcerative colitis, where they drive and regulate …

Background Vedolizumab [VDZ] is an anti-integrin monoclonal antibody effective in
ulcerative colitis [UC] and Crohn's disease [CD]. Several real-world experience [RWE] …

Background Nontraditional combination of existing therapies is often the only option to avoid
surgery in refractory inflammatory bowel disease (IBD) patients. We aim to assess the …

Background: Ustekinumab is an effective therapy for Crohn disease currently approved for
adults. Off-label use in the pediatric population is increasing, but its effectiveness in this age …